GALANDRA, CATERINA
 Distribuzione geografica
Continente #
EU - Europa 89
NA - Nord America 88
AS - Asia 80
SA - Sud America 13
AF - Africa 11
Totale 281
Nazione #
US - Stati Uniti d'America 80
IT - Italia 38
SG - Singapore 29
CN - Cina 20
RU - Federazione Russa 18
DE - Germania 11
HK - Hong Kong 11
VN - Vietnam 9
BR - Brasile 8
ZA - Sudafrica 7
FR - Francia 6
GB - Regno Unito 4
MX - Messico 4
MA - Marocco 3
BD - Bangladesh 2
CA - Canada 2
EC - Ecuador 2
ES - Italia 2
FI - Finlandia 2
IN - India 2
PL - Polonia 2
TR - Turchia 2
BE - Belgio 1
BO - Bolivia 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
EG - Egitto 1
HN - Honduras 1
HR - Croazia 1
ID - Indonesia 1
JO - Giordania 1
JP - Giappone 1
KZ - Kazakistan 1
LT - Lituania 1
NL - Olanda 1
PY - Paraguay 1
SI - Slovenia 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 281
Città #
San Jose 24
Singapore 16
Rome 12
Hong Kong 10
Ashburn 8
Beijing 7
Council Bluffs 7
Milan 6
Ho Chi Minh City 5
Johannesburg 5
Los Angeles 5
Boardman 4
Dallas 4
Lauterbourg 4
Moscow 4
Munich 4
Redondo Beach 3
Casablanca 2
Dhaka 2
Frankfurt am Main 2
Hanoi 2
Naples 2
Nuremberg 2
Orem 2
Osio Sotto 2
Querétaro 2
Quito 2
Santa Clara 2
Treviso 2
Turin 2
Turku 2
Warsaw 2
Almaty 1
Amman 1
Ankara 1
Asunción 1
Atlanta 1
Baoding 1
Belo Horizonte 1
Biên Hòa 1
Bonito 1
Brno 1
Cairo 1
Cape Town 1
Changzhou 1
Cochabamba 1
Düsseldorf 1
El Jadida 1
Elk Grove Village 1
Estrela dOeste 1
Florence 1
Glendale 1
Guangzhou 1
Guiyang 1
Haikou 1
Iguape 1
Istanbul 1
Itaquaquecetuba 1
Jakarta 1
Kowloon City 1
Las Vegas 1
Liège 1
Ljubljana 1
Ludhiana 1
Madrid 1
Magenta 1
Manchester 1
Mexico City 1
Milwaukee 1
Montreal 1
Nagpur 1
Natal 1
Palotina 1
Parma 1
Pavia 1
Piscataway 1
Pretoria 1
Santo Domingo 1
Schaumburg 1
Tashkent 1
Tegucigalpa 1
Thanh Mỹ Tây 1
Tokyo 1
Toronto 1
Valencia 1
Volta Redonda 1
Xinxiang 1
Zagreb 1
Totale 214
Nome #
Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson's disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol 106
Serum dysregulation of serine and glycine metabolism as predictive biomarker for cognitive decline in frail elderly subjects 66
Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2) 57
Team Science Approaches to Unravel Monogenic Parkinson's Disease on a Global Scale 44
1H-NMR-based metabolomics identifies disrupted betaine metabolism as distinct serum signature of pre-frailty 10
RAB32 mutation in Parkinson's disease [2] 4
Male sex accelerates cognitive decline in GBA1 Parkinson’s disease 2
Independent serum metabolomics approaches identify disrupted glutamic acid and serine metabolism in Parkinson’s disease patients 1
Totale 290
Categoria #
all - tutte 1.179
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.179


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202422 0 0 0 0 0 4 6 4 0 3 2 3
2024/202597 6 2 1 0 1 9 14 4 27 7 8 18
2025/2026171 13 4 23 17 21 5 30 6 15 16 16 5
Totale 290